Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Forsteo ® (teriparatide)
Forsteo® (teriparatide): Use in Patients with Myeloma
Use of Forsteo in patients with multiple myeloma is not approved.
Patients with skeletal malignancies or bone metastases should be excluded from treatment with teriparatide (contraindication).1
Osteoporosis or pathological fracture may be one of the first signs of multiple myeloma. Rapidly declining bone mineral density or low trauma pathological fracture may warrant further evaluation, including testing for monoclonal gammopathy.2
2. Faiman B, Licata AA. New tools for detecting occult monoclonal gammopathy, a cause of secondary osteoporosis. Cleve Clin J Med. 2010;77(4):273-278. https://mdedge-files-live.s3.us-east-2.amazonaws.com/files/s3fs-public/issues/articles/media_12ffa61_273.pdf
Date of Last Review: March 03, 2020